By using our website, you agree to our use of cookies.

Skip Navigation

Invest in COMPASS Pathways PLC on Stash

COMPASS Pathways PLC is a mental health care company. The Company is focused on developing treatments for people suffering with mental health challenges. It is initially focused on treatment-resistant depression (TRD). It is developing COMP360, a polymorphic crystalline formulation of psilocybin. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. The psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360. The Company is developing COMP360 in conjunction with psychological support in a Phase-IIb trial.

To buy fractional shares of COMPASS Pathways PLC stock, you'll need to sign up for Stash and open a personal portfolio.
COMPASS Pathways PLC

Ticker: CMPS

COMPASS Pathways PLC

$5.68

+9.65%

(1W)
Nov ’25Dec ’25$5$6$6

$

CMPS Performance Breakdown

Share Price

 

$5.68

Today's change

 

11.59%

Year to date change (YTD)

 

36.87%

Dividend yield

 

0.0

Last dividend paid

 

N/A

Last dividend pay date

 

N/A

About CMPS

COMPASS Pathways PLC is a mental health care company. The Company is focused on developing treatments for people suffering with mental health challenges. It is initially focused on treatment-resistant depression (TRD). It is developing COMP360, a polymorphic crystalline formulation of psilocybin. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. The psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360. The Company is developing COMP360 in conjunction with psychological support in a Phase-IIb trial.

COMPASS Pathways PLC Stock Ticker

CMPS

For more information

https://compasspathways.com

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

COMPASS Pathways PLC stock news

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,8 recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.1

Learn how to invest

Get professional advice and education at every step.

How to buy COMPASS Pathways PLC stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Stash offers two subscription plans: Stash Growth and Stash+.

Once your market order of COMPASS Pathways PLC stock is complete, you'll officially be a shareholder of COMPASS Pathways PLC!

Invest in COMPASS Pathways PLC on Stash

COMPASS Pathways PLC is a mental health care company. The Company is focused on developing treatments for people suffering with mental health challenges. It is initially focused on treatment-resistant depression (TRD). It is developing COMP360, a polymorphic crystalline formulation of psilocybin. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. The psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360. The Company is developing COMP360 in conjunction with psychological support in a Phase-IIb trial.

To buy fractional shares of COMPASS Pathways PLC stock, you'll need to sign up for Stash and open a personal portfolio.